The Drugs Controller General of India (DCGI) has approved the second and third phase clinical trials of Sputnik-5 vaccine made by Russia to Indian drug manufacturer Dr. Reddy’s Laboratories. On September 16, the Russian Direct Investment Fund (RDIF) and Dr. Reddy’s Laboratories Limited agreed to collaborate on clinical trial (clinical) trials and delivery of the Sputnik-5 Kovid-19 vaccine in India.
The Sputnik-5 vaccine has been developed jointly by the Russian Direct Investment Fund (RDIF) and the Gemaleya National Research Center of Epidemiology and Microbiology, which was registered on 11 August.This is an important development, which allows us to introduce clinical trials in India and we are committed to bringing a safe and effective vaccine to combat the epidemic,” V. Prasad said in a statement.
The Russian Direct Investment Fund (RDIF) said in a statement issued in this regard,
RDIF will supply 10 million doses of vaccine to Dr.Reddy Laboratories on the basis of regulatory permission in India.”
The statement further stated, “The Sputnik-5 vaccine is undergoing clinical trials for the coronavirus pandemic.
Delivery may begin in late 2020 after successful testing and completion of vaccine registration by regulatory authorities in India.”
RDIF Stated that its agreement with Dr. Reddy Laboratories demonstrates that countries and organizations are conscious of protecting their people from the corona virus epidemic.